Skip to Main Content

Paper Details

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
Clin Cancer Res
44
2022
Author NameAffiliation
Anna Maria StornioloIndiana University Melvin and Bren Simon Cancer Center
Larissa A KordeNational Cancer Institute
  • 1 - 2

Datasets

Release 1.2